We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
In vitro pharmacoregulation of CC chemokine ligand 5 and its receptor CCR5 in diffuse lung diseases.
- Authors
Sekerova, Veronika; Subrtova, Daniela; Mrazek, Frantisek; Gibejova, Agata; Kolek, Vitezslav; du Bois, Roland M.; Petrek, Martin
- Abstract
B ackground CC chemokine ligand (CCL)5 and its receptor CCR5 contribute to leukocyte migration into lungs of patients with diffuse lung diseases (DLD). Pharmacological regulation of CCL5 and CCR5 expression was therefore explored in bronchoalveolar cells obtained from patients with DLD. Methods Cells from 21 patients were co-cultivated in vitro with tumour necrosis factor-α and dexamethasone, cyclosporin A (CyA) or pentoxifylline. Chemokine mRNA expression and protein production was assessed by reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. Results Dexamethasone altered CCL5 mRNA expression and suppressed its protein levels. CyA inhibited chemokine mRNA expression but not protein production. Pentoxifylline did not affected chemokine expression. Both dexamethasone and CyA suppressed CCR5 mRNA transcripts. Conclusion In conclusion, while dexamethasone downregulates the CCL5 functional form, CyA and pentoxifylline have no effects on CCL5 protein. These data provide in vitro correlation for clinical applications of immunomodulators in therapy of DLD.
- Subjects
CHEMOKINES; LUNG diseases; CYTOKINES
- Publication
Mediators of Inflammation, 2003, Vol 12, Issue 4, p215
- ISSN
0962-9351
- Publication type
Academic Journal
- DOI
10.1080/09629350310001599657